Induction of human leukemia HL-60 cell differentiation via a PKC/ERK pathway by helenalin, a pseudoguainolide sesquiterpene lactone

被引:18
作者
Kim, SH
Oh, SM
Kim, TS [1 ]
机构
[1] Chonnam Natl Univ Hosp, Genome Res Ctr Hematopoiet Dis, Kwangju 501757, South Korea
[2] Chonnam Natl Univ, Coll Pharm, Immunol Lab, Kwangju 500757, South Korea
关键词
helenalin; cell differentiation; protein kinase C; extracellular signal-regulated kinase; nuclear factor-kappa B;
D O I
10.1016/j.ejphar.2005.02.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Helenalin, a cell-permeable pseudoguainolide sesquiterpene lactone, is a potent anti-inflammatory agent that inhibits nuclear factor-kappaB (NF-kappa B) DNA binding activity. In this report, we investigated the effect of helenalin on cellular differentiation in the human promyelocytic leukemia HL-60 cell culture system. Helenalin by itself markedly induced HL-60 cell differentiation in a concentration-dependent manner. Cytofluorometric analysis and cell morphologic studies indicated that helenalin induced cell differentiation predominantly into granulocytes. Protein kinase C (PKC) and extracellular signal-regulated kinase (ERK) inhibitors significantly inhibited HL-60 cell differentiation induced by helenalin, while p38 mitogen-activated protein kinase (MAPK) inhibitors did not. Moreover, helenalin enhanced PKC activity and protein level of PKC beta I and PKC beta II isoforms, and also increased the level of pERK in a concentration-dependent manner. In addition, the enhanced levels of cell differentiation closely correlated with the decreased levels of NF-kappa B binding activity by helenalin. These results indicate that PKC, ERK, and NF-kappa B may be involved in HL-60 cell differentiation induced by helenalin. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:89 / 97
页数:9
相关论文
共 36 条
  • [1] PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO
    ALESSI, DR
    CUENDA, A
    COHEN, P
    DUDLEY, DT
    SALTIEL, AR
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) : 27489 - 27494
  • [2] BEERE HM, 1993, ANTI-CANCER DRUG DES, V8, P299
  • [3] Bertagnolo V, 1999, CANCER RES, V59, P542
  • [4] INDUCTION OF DIFFERENTIATION OF THE HUMAN PROMYELOCYTIC LEUKEMIA-CELL LINE (HL-60) BY RETINOIC ACID
    BREITMAN, TR
    SELONICK, SE
    COLLINS, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (05): : 2936 - 2940
  • [5] Protein kinase C: A worthwhile target for anticancer drugs?
    Caponigro, F
    French, RC
    Kaye, SB
    [J]. ANTI-CANCER DRUGS, 1997, 8 (01) : 26 - 33
  • [6] Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-γ and nuclear factor-κB
    Chung, SW
    Kang, BY
    Kim, SH
    Pak, YK
    Cho, D
    Trinchieri, G
    Kim, TS
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (42) : 32681 - 32687
  • [7] Coligan J, 1995, CURRENT PROTOCOLS IM
  • [8] TERMINAL DIFFERENTIATION OF HUMAN PROMYELOCYTIC LEUKEMIA-CELLS INDUCED BY DIMETHYL-SULFOXIDE AND OTHER POLAR COMPOUNDS
    COLLINS, SJ
    RUSCETTI, FW
    GALLAGHER, RE
    GALLO, RC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (05) : 2458 - 2462
  • [9] HALL IH, 1988, ANTICANCER RES, V8, P33
  • [10] Hehner SP, 1999, J IMMUNOL, V163, P5617